Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.

出版年份 2019 全文链接

标题

作者

关键词

出版物

Volume 37, Issue 15_suppl, Pages 4010-4010

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2019-05-28

DOI

10.1200/jco.2019.37.15_suppl.4010

Discuss science. Find collaborators. Network.

Join a conversation

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started